Document:

EX-10.3

 Exhibit 10.3 

AMENDMENT TO SHARE PURCHASE AGREEMENT 

This AMENDMENT TO SHARE PURCHASE AGREEMENT (the “Amendment”), dated as of June 3, 2019, is entered into between GENEPOC
INC., a corporation incorporated under the laws of Canada (“Seller”), MERIDIAN BIOSCIENCE CANADA INC., a corporation incorporated under the laws of British Columbia (“Buyer”), THE SHAREHOLDERS OF SELLER (the
“Shareholders”), APRÈS-DEMAIN HOLDING SA, in its capacity of Shareholders’ Representative, and MERIDIAN BIOSCIENCE, INC. 

RECITALS 
 WHEREAS
on April 29, 2019, a share purchase agreement (the “Purchase Agreement”) was entered into between the Seller, the Buyer, the Shareholders solely for the purpose of Section 8.01 thereof,
Après-Demain Holding SA solely in its capacity of Shareholders’ Representative, and Meridian Bioscience, Inc., solely for the purpose of Sections 2.06, 2.07 and 8.02 thereof, pursuant to which Buyer agreed to
purchase, on the Closing Date (as such term is defined in the Purchase Agreement) and the Seller agreed to sell, all of shares held by Seller in the share capital of Genepoc Canada Inc. as of the Closing Date; 

WHEREAS Schedule 2 to the Purchase Agreement provides, among other things, a description of the GI Panel Assay including the
description of the assay specifications relating to the GI Bacterial Panel under development by the Seller; 
 WHEREAS on or about
May 15, 2019, the Seller and the Buyer reached an agreement about removing the Lari subspecies from the GI Panel Assay; 
 WHEREAS on
or about May 30, 2019, the Seller and the Buyer reached an agreement on a revised version of the sample calculation of the Closing Working Capital, as well as on a revised amount for the Target Working Capital; and 

WHEREAS the parties hereto therefore wish to amend the Purchase Agreement as of and from the date hereof in order to reflect the above
mentioned agreements. 
 NOW THEREFORE, in consideration of the premises and mutual agreements herein contained, and for other good and
valuable consideration (the receipt and sufficiency of which are acknowledged by each party), the parties hereto agree as follows: 

ARTICLE 1 

INTERPRETATION 
  

	1.1	 Definitions 

In this Amendment, all defined terms shall have the meanings ascribed thereto in the Purchase Agreement, unless otherwise defined herein. 

 ARTICLE 2 

AMENDMENT TO PURCHASE AGREEMENT 
  

	2.1	 Replacement of Schedule 2 of the Purchase Agreement 

Schedule 2 to the Purchase Agreement is hereby deleted in its entirety and replaced by the revised and amended Schedule 2
attached hereto. All references to Schedule 2 in the Purchase Agreement, including in the definitions of GI Panel Assay and RI Assay Panel shall refer to the revised and amended Schedule 2 attached to this Amendment. 

 

	2.2	 Replacement of Exhibit D of the Purchase Agreement 

Exhibit D to the Purchase Agreement is hereby deleted in its entirety and replaced by the revised and amended Exhibit D attached
hereto. All references to Exhibit D in the Purchase Agreement, including in the definition of Sample Working Capital Statement shall refer to the revised and amended Exhibit D attached to this Amendment. 

 

	2.3	 Amendment of Paragraph 2.08 (a) 

Paragraph 2.08 (a) of the Purchase Agreement is hereby deleted in its entirety and replaced by the following: 

“(a) Closing Adjustment. 

(i) At the Closing, the Base Purchase Price shall be adjusted in the following manner: 

(A) either (1) an increase by the amount, if any, by which the Estimated Closing Working Capital (as determined in
accordance with Section 2.08(a)(ii)) is greater than CA$500,000 (the “Target Working Capital”), or (2) a decrease by the amount, if any, by which the Estimated Closing Working Capital is less than the Target Working
Capital; 
 (B) a decrease by the amount of Estimated Indebtedness. 

The net amount after giving effect to the adjustments listed above shall be the actual “Base Cash Payment to be paid at
Closing”. 
 (ii) At least three (3) Business Days before the Closing, Seller shall prepare and deliver to
Buyer a statement setting forth its good faith estimate of Closing Indebtedness assumed by the Company under the Asset Transfer Agreement (the “Estimated Indebtedness”) and Closing Working Capital transferred to the Company under
the Asset Transfer Agreement (the “Estimated Closing Working Capital”), and a certificate of the Chief Financial Officer of the Seller (without personal liability) that the calculation of Estimated Indebtedness and the Estimated
Closing 

 
Working Capital Statement were prepared in accordance with CASPE applied using the same accounting methods, practices, principles, policies and procedures, with consistent classifications,
judgments and valuation and estimation methodologies that were used in the preparation of the Audited Financial Statements for the most recent fiscal year end.” 
  

	2.4	 Effect of Amendment 

Except with respect to the modifications expressly implemented in accordance herewith, the content of this Amendment shall not in any way be
interpreted as modifying the terms and conditions of the Purchase Agreement and it contains no other modification, whether implicit or ancillary and no other change in any other respect. Except for Schedule 2 which shall be replaced by the
revised and amended Schedule 2 attached hereto, the Purchase Agreement remains in full force and effect, unamended. 

ARTICLE 3 
 GENERAL

  

	3.1	 Further Assurances 

Each of the parties hereto shall from time to time execute and deliver all such further documents and instruments and do all acts and things as
another party may reasonably require in connection with this Amendment to effectively carry out or better evidence or perfect the full intent and meaning of this Amendment. 
  

	3.2	 Successors, Assigns and Assignment 

This Amendment will enure to the benefit of and be binding upon the respective successors and permitted assigns of the parties hereto. This
Amendment may not be assigned by any party other than in compliance with and concurrently with the Purchase Agreement. 
  

	3.3	 Amendments and Waivers 

No amendment of this Amendment or further amendment to the Purchase Agreement shall be valid or binding unless set forth in writing and duly
executed by all parties hereto. No waiver of any breach of any provision of this Amendment shall be effective or binding unless made in writing and signed by the party purporting to give same and, unless otherwise provided, will be limited to the
specific breach waived. 

	3.4	 Governing Law and Forum 

(a) This Amendment shall be governed by and construed in accordance with the internal laws of the Province of Quebec and the federal laws of
Canada applicable therein and shall be treated in all respects, as a Quebec contract. 
 (b) Any legal suit, action or proceeding arising out
of or based upon this Amendment shall be heard and determined by the courts of the province of Quebec, district of Montreal. 
  

	3.5	 Severability 

If any provision of this Amendment is determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect,
such determination shall not impair or affect the validity, legality or enforceability of the remaining provisions hereof, and each provision is hereby declared to be separate, severable and distinct. 

 

	3.6	 Counterparts 

This Amendment may be executed in one or more counterparts, each of which shall conclusively be deemed to be an original but all of which taken
together shall be deemed to constitute one and the same agreement. A facsimile transmission of this Amendment bearing a signature on behalf of a party shall be legal and binding on such Party. 

 

	3.7	 Language 

The parties hereto acknowledge that they have required that this Amendment and all related documents be drawn up in English. Les parties aux
présentes reconnaissent avoir exigé que le présent amendement et tous les documents connexes soient rédigés en anglais. 

(Remainder of this page left blank intentionally; Signature Pages Follow) 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the date first
written above by their respective officers thereunto duly authorized. 
 SELLER: 

 

			
	GENEPOC INC.
		
	By:	 	/s/ Patrice Allibert
	Name:	 	Patrice Allibert
	Title:	 	President

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first
written above by their respective officers thereunto duly authorized. 
 BUYER: 

 

			
	MERIDIAN BIOSCIENCE CANADA INC.
		
	By:	 	/s/ Jack Kenny
	Name:	 	Jack Kenny
	Title:	 	Director

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the date first
written above by their respective officers thereunto duly authorized. 
 MERIDIAN PARENTCO: 

 

			
	MERIDIAN BIOSCIENCE, INC.
		
	By:	 	/s/ Jack Kenny
	Name:	 	Jack Kenny
	Title:	 	President and Chief Executive Officer

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the date first
written above by their respective officers thereunto duly authorized. 
 SHAREHOLDER’S REPRESENTATIVE: 

 

			
	APRÈS-DEMAIN HOLDINGS SA
		
	By:	 	/s/ Thierry Mauvernay
	Name:	 	Thierry Mauvernay
	Title:	 	President

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the date first
written above by their respective officers thereunto duly authorized. 
  

			
	 INFECTIO RECHERCHE INC.

		
		 	/s/ Michel G. Bergeron
	By:	 	Michel G. Bergeron
	Title:	 	

					
			
	/s/ Patrice Allibert	 		 	/s/ Sébastien Chapdelaine
	PATRICE ALLIBERT	 		 	SÉBASTIEN CHAPDELAINE
			
	/s/ Maurice Boissinot	 		 	/s/ Alban D’Amour
	MAURICE BOISSINOT	 		 	ALBAN D’AMOUR
			
	/s/ Ann Huletsky	 		 	/s/ Regis Peytavi
	ANN HULETSKY	 		 	REGIS PEYTAVI
			
	/s/ Michel G. Bergeron	 		 	/s/ Marie-Josée Paré
	MICHEL G. BERGERON	 		 	MARIE-JOSÉE PARÉ
			
	/s/ Herbert Torfs	 		 	Jean Côté
	HERBERT TORFS	 		 	JEAN CÔTÉ
			
	/s/ Dany LeBlanc	 		 	  

	DANY LEBLANCEX-10.4

 Exhibit 10.4 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS 

EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] 

AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT 

This AMENDMENT NO. 3 TO SHARE PURCHASE AGREEMENT dated as of December 21, 2020, is entered into between
APRÈS-DEMAIN DIAGNOSTICS INC. (formerly known as Genepoc Inc.), a corporation incorporated under the laws of Canada (“Seller”), MERIDIAN BIOSCIENCE CANADA INC., a corporation
incorporated under the laws of British Columbia (“Buyer”), APRÈS-DEMAIN SA (formerly known as APRÈS-DEMAIN HOLDING SA), in its capacity of
Shareholders’ Representative, and MERIDIAN BIOSCIENCE, INC. 
 RECITALS 

WHEREAS on April 29, 2019, a share purchase agreement (as amended by the Amendments No. 1 and No. 2 dated respectively
June 3, 2019 and September 29, 2020, the “Purchase Agreement”) was entered into between the Seller, Meridian Bioscience Canada Inc. (a predecessor by amalgamation of Buyer), the Shareholders solely for the purpose of
Sections 5.03, 8.01 and 10.05 thereof, Après-Demain SA (formerly known as Après-Demain Holding SA) solely in its capacity of Shareholders’
Representative, and Meridian Bioscience, Inc., solely for the purpose of Sections 2.06, 2.07 and 8.02 thereof, pursuant to which Meridian Bioscience Canada Inc. (a predecessor by amalgamation of Buyer) agreed to
purchase, on the Closing Date (as such term is defined in the Purchase Agreement) and the Seller agreed to sell, all of the shares held by Seller in the share capital of Genepoc Canada Inc. (defined in the Purchase Agreement as the
“Company”) as of the Closing Date; 
 WHEREAS Meridian Bioscience Canada Inc. (a predecessor by amalgamation of
Buyer) and the Company amalgamated on June 3, 2019, to continue as the Buyer; 
 WHEREAS by Section 10.05 of
the Purchase Agreement, Après-Demain SA was appointed as “Shareholders’ Representative” whereby it can act as “agent, proxy and attorney-in-fact for” each Shareholder in order, among other matters, “(b) to execute and deliver on behalf of such Shareholder any amendment or waiver hereto, (c) to take all other actions to
be taken by or on behalf of such Shareholder in connection herewith”; 
 WHEREAS by Section 10.10 of the Purchase
Agreement, the Purchase Agreement “may only be amended, modified or supplemented by an agreement in writing signed by Buyer, Seller and Shareholders’ Representative”; 

WHEREAS Schedule 2 to the Purchase Agreement provides, among other things, a description of the RI Panel Assay including the
description of the assay specifications relating to the RI Viral Panel under development by the Seller; 
 WHEREAS the Seller and the Buyer
have reached an agreement to revise the RI Viral Panel as described on Schedule 2 to the Purchase Agreement in order to remove the SARS-COV-2 from the targets;
and 
 WHEREAS the parties hereto therefore wish to amend the Purchase Agreement as of and from the date hereof in order to reflect, amongst
others, the above mentioned agreements as well as other changes arising therefrom or related thereto. 
 NOW THEREFORE, in consideration of
the premises and mutual agreements herein contained, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), the parties hereto agree as follows: 

 ARTICLE 1 

INTERPRETATION 
  

	1.1	 Definitions 

In this Amendment No. 3 (as defined below), all defined terms shall have the meanings ascribed thereto in the Purchase Agreement, unless
otherwise defined herein. 
 ARTICLE 2 

AMENDMENT TO PURCHASE AGREEMENT 
  

	2.1	 Amendment to Article I—Definitions 

(i) One additional definition shall be added to Article I of the Purchase Agreement which state the following: 

“Amendment No. 3” means the Amendment No. 3 to Share Purchase Agreement dated December 21, 2020
by and between Seller, Buyer, Shareholders’ Representative and Meridian ParentCo.” 
 (ii) The definitions “Amendment
No. 2” is hereby deleted and replaced by the following: 
 “Amendment No. 2”
means the Amendment No. 2 to Share Purchase Agreement dated September 29, 2020 by and between Seller, Buyer, Shareholders’ Representative and Meridian ParentCo.” 

 

	2.2	 Replacement of Schedule 2 of the Purchase Agreement 

Schedule 2 to the Purchase Agreement is hereby deleted in its entirety and replaced by the revised and amended Schedule 2
attached hereto. All references to Schedule 2 in the Purchase Agreement, including in the definitions of GI Panel Assay and RI Panel Assay shall refer to the revised and amended Schedule 2 attached to this Amendment No. 3. 

ARTICLE 3 
 GENERAL

  

	3.1	 Shareholders Representative 

The Shareholders’ Representative represents and warrants to the Buyer and to Meridian Bioscience, Inc. that (i) it has not renounced
or otherwise terminated the mandate given to it in the Purchase Agreement to represent the Shareholders as set forth in the Purchase Agreement and (ii) it has not received any notice from any Shareholder that such Shareholder has or will
renounce the mandate given by it in the Purchase Agreement to the Shareholders’ Representative, and that accordingly the Shareholders’ Representative has the right to bind the Shareholders for the purposes set forth in this Amendment
No. 3. 
  

	3.2	 Further Assurances 

Each of the parties hereto shall from time to time execute and deliver all such further documents and instruments and do all acts and things as
another party may reasonably require in connection with this Amendment No. 3 to effectively carry out or better evidence or perfect the full intent and meaning of this Amendment No. 3. 

  
 - 2 - 

	3.3	 Successors, Assigns and Assignment 

This Amendment No. 3 will enure to the benefit of and be binding upon the respective successors and permitted assigns of the parties
hereto. This Amendment No. 3 may not be assigned by any party other than in compliance with and concurrently with the Purchase Agreement. 
  

	3.4	 Amendments and Waivers 

No amendment of this Amendment No. 3 or further amendment to the Purchase Agreement shall be valid or binding unless set forth in writing
and duly executed by all parties hereto. No waiver of any breach of any provision of this Amendment No. 3 shall be effective or binding unless made in writing and signed by the party purporting to give same and, unless otherwise provided, will
be limited to the specific breach waived. 
  

	3.5	 Governing Law and Forum 

(a) This Amendment No. 3 shall be governed by and construed in accordance with the internal laws of the Province of Quebec and the federal
laws of Canada applicable therein and shall be treated in all respects, as a Quebec contract. 
 (b) Any legal suit, action or proceeding
arising out of or based upon this Amendment No. 3 shall be heard and determined by the courts of the province of Quebec, district of Montreal. 
  

	3.6	 Severability 

If any provision of this Amendment No. 3 is determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any
respect, such determination shall not impair or affect the validity, legality or enforceability of the remaining provisions hereof, and each provision is hereby declared to be separate, severable and distinct. 

 

	3.7	 Counterparts 

This Amendment No. 3 may be executed in one or more counterparts, each of which shall conclusively be deemed to be an original but all of
which taken together shall be deemed to constitute one and the same agreement. A facsimile transmission of this Amendment No. 3 bearing a signature on behalf of a party shall be legal and binding on such Party. 

 

	3.8	 Language 

The parties hereto acknowledge that they have required that this Amendment No. 3 and all related documents be drawn up in English. Les
parties aux présentes reconnaissent avoir exigé que le présent amendement et tous les documents connexes soient rédigés en anglais. 

(Remainder of this page left blank intentionally; Signature Pages Follow) 

  
 - 3 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 3 to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

			
	SELLER:	  	

  

			
	APRÈS-DEMAIN DIAGNOSTICS INC.
		
	By:	 	/s/ Tanja Dowe
	Name:	 	Tanje Dowe
	Title:	 	President

  
 - 4 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 3 to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

			
	BUYER:	  	

  

			
	MERIDIAN BIOSCIENCE CANADA INC.
		
	By:	 	/s/ Bryan Baldasare
	Name:	 	Bryan Baldasare
	Title:	 	Director

  
 - 5 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 3 to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

			
	 MERIDIAN PARENTCO:
	  	

  

			
	MERIDIAN BIOSCIENCE, INC.
		
	By:	 	/s/ Bryan Baldasare
	Name:	 	Bryan Baldasare
	Title:	 	EVP, CFO

  
 - 6 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 3 to be executed as of the
date first written above by their respective officers thereunto duly authorized. 
  

			
	 SHAREHOLDER’S REPRESENTATIVE:
	  	

  

			
	APRÈS-DEMAIN SA
		
	By:	 	/s/ Thierry Mauvernay
	Name:	 	Thierry Mauvernay
	Title:	 	President

  
 - 7 - 

 SCHEDULE 2 

Molecular IVD Assay Specifications: GI Bacterial Panel and RI Viral Panel 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]